StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Rating) in a research note issued to investors on Friday. The firm set a “sell” rating on the biotechnology company’s stock.
Several other analysts have also issued reports on the company. Zacks Investment Research raised vTv Therapeutics from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a report on Thursday. Cantor Fitzgerald assumed coverage on vTv Therapeutics in a research note on Friday, February 18th. They issued an “overweight” rating and a $5.00 price objective for the company.
Shares of VTVT opened at $0.40 on Friday. vTv Therapeutics has a one year low of $0.39 and a one year high of $2.88. The firm has a market capitalization of $36.18 million, a P/E ratio of -1.83 and a beta of -1.43. The business has a fifty day moving average of $0.65 and a 200 day moving average of $0.92.
Large investors have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new stake in shares of vTv Therapeutics in the third quarter worth about $26,000. GSA Capital Partners LLP purchased a new stake in shares of vTv Therapeutics in the third quarter worth about $177,000. Rafferty Asset Management LLC purchased a new stake in shares of vTv Therapeutics in the third quarter worth about $83,000. Geode Capital Management LLC lifted its position in shares of vTv Therapeutics by 77.2% in the third quarter. Geode Capital Management LLC now owns 347,635 shares of the biotechnology company’s stock worth $531,000 after buying an additional 151,435 shares in the last quarter. Finally, Morgan Stanley raised its position in vTv Therapeutics by 114.6% during the third quarter. Morgan Stanley now owns 78,895 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 42,139 shares during the period. Institutional investors own 7.35% of the company’s stock.
vTv Therapeutics Company Profile (Get Rating)
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.
- Get a free copy of the StockNews.com research report on vTv Therapeutics (VTVT)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.